Literature DB >> 15818174

Bladder cancer.

Lester S Borden1, Peter E Clark, M Craig Hall.   

Abstract

PURPOSE OF REVIEW: This article reviews the recent literature concerning important issues in the management of patients with bladder cancer. A brief overview of all aspects of bladder cancer including the etiology, diagnosis, and treatment are discussed with a focus on recent advances. RECENT
FINDINGS: Bladder cancer is a significant cause of morbidity and mortality. The treatment for bladder cancer should be based on individual patient risk assessment and should include a multidisciplinary approach. In patients with superficial bladder cancer, research has focused on improving and optimizing intravesical therapy to reduce tumor recurrence and progression as well as on methods to better select the most appropriate treatment for patients with high-risk features. The important prognostic and therapeutic role of lymphadenectomy during radical cystectomy has become apparent and recent work has attempted to better define what should be considered the standard for lymph node dissection. Finally, in an attempt to improve survival, advances have been made using systemic chemotherapy in both the perioperative settings as well as for treatment of metastatic bladder cancer.
SUMMARY: Research continues to improve our understanding of bladder cancer. This ongoing investigation is currently being translated to the bedside with refinements in the diagnosis and treatment of patients with bladder cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15818174     DOI: 10.1097/01.cco.0000156985.47984.9e

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  8 in total

1.  Expression of CHD1L in bladder cancer and its influence on prognosis and survival.

Authors:  Feng Tian; Feng Xu; Zheng-Yu Zhang; Jing-Ping Ge; Zhi-Feng Wei; Xiao-Feng Xu; Wen Cheng
Journal:  Tumour Biol       Date:  2013-06-27

Review 2.  The Role of Adjuvant Single Postoperative Instillation of Gemcitabine for Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.

Authors:  Georgios Koimtzis; Vyron Alexandrou; Christopher G Chalklin; Eliot Carrington-Windo; Mark Ramsden; Nikolaos Karakasis; Kit W Lam; Georgios Tsakaldimis
Journal:  Diagnostics (Basel)       Date:  2022-05-06

3.  Survival in bladder and renal cell cancers is familial.

Authors:  Jianguang Ji; Asta Försti; Jan Sundquist; Per Lenner; Kari Hemminki
Journal:  J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 10.121

4.  Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer.

Authors:  Sabrina Thalita Reis; Katia Ramos M Leite; Luís Felipe Piovesan; José Pontes-Junior; Nayara Izabel Viana; Daniel Kanda Abe; Alexandre Crippa; Caio Martins Moura; Sanarelly Pires Adonias; Miguel Srougi; Marcos Francisco Dall'Oglio
Journal:  BMC Urol       Date:  2012-06-13       Impact factor: 2.264

5.  Comparative analysis of early perioperative outcomes following radical cystectomy by either the robotic or open method.

Authors:  Anton Galich; Samuel Sterrett; Tanya Nazemi; Garrett Pohlman; Lynette Smith; K C Balaji
Journal:  JSLS       Date:  2006 Apr-Jun       Impact factor: 2.172

6.  Surveillance and treatment of non-muscle-invasive bladder cancer in the USA.

Authors:  Daniel A Barocas; Denise R Globe; Danielle C Colayco; Ahunna Onyenwenyi; Amanda S Bruno; Thomas J Bramley; Rachel J Spear
Journal:  Adv Urol       Date:  2012-05-10

7.  lncRNA MIR4435-2HG Accelerates the Development of Bladder Cancer through Enhancing IQGAP3 and CDCA5 Expression.

Authors:  Tao Yang; Yan Li; Gang Wang; Liuxiong Guo; Fuzhen Sun; Shoubin Li; Xinna Deng; Junjiang Liu
Journal:  Biomed Res Int       Date:  2022-08-12       Impact factor: 3.246

8.  Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p.

Authors:  Ming Sun; Xuefeng Liu; Wenyan Zhao; Bin Zhang; Peng Deng
Journal:  BMC Cancer       Date:  2022-03-23       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.